文献速递生殖医学

供卵者最佳抗苗勒管激素水平:一项全国数据库分析

Optimal antimüllerian hormone levels in oocyte donors: a national database analysis.
PubMed 文献 · Fertil Steril · 2023-11-08

该回顾性队列研究基于美国35家IVF中心2013至2021年供卵银行数据库,分析3,871个供卵解冻周期,比较高AMH组(≥5 ng/mL,n=1,821)与参照组(<5 ng/mL,n=2,050)的结局。结果显示两组每周期可用胚胎数中位数分别为2(2-4)与2(1-3),持续妊娠率分别为45.4%与43.5%,无显著差异。

要点

  • 高AMH组(≥5 ng/mL)每批可用胚胎数中位数2(2-4)高于参照组2(1-3),RR 1.06(95%CI 1.01-1.12)
  • 计划移植的受体中,高AMH组持续妊娠率45.4%与参照组43.5%无差异,RR 1.04(95%CI 0.94-1.15)
  • 高AMH供卵者的胚胎结局至少不劣于AMH<5 ng/mL者,可让受体和医生放心

核心结论

  • 这项大型全国数据库研究观察到,供卵者高AMH水平(≥5 ng/mL)与受体首次胚胎移植后的持续妊娠率无关联。
  • 基于这些发现,受体和医生可以放心,高AMH水平的供卵者预期可产生至少与AMH<5 ng/mL供卵者同样好的结局。

研究设计与样本

  • 回顾性队列研究,数据来自供卵银行数据库,纳入美国35家体外受精中心2013至2021年间使用玻璃化供卵的周期。
  • 每个受体纳入首个收到且计划授精和胚胎移植的卵子批,共分析3,871个供卵解冻周期。
  • 按供卵者血清AMH浓度分层为高AMH组(≥5 ng/mL,n=1,821)和参照组(<5 ng/mL,n=2,050),采用广义估计方程模型处理同一供卵者贡献多个批次的情况。

主要发现

  • 每批可用胚胎数中位数在高AMH组为2(2-4),参照组为2(1-3),RR 1.06(95%CI 1.01-1.12)。
  • 计划胚胎移植的受体中,高AMH组持续妊娠率为45.4%,参照组为43.5%,RR 1.04(95%CI 0.94-1.15),无差异。
  • 进行胚胎非整倍体植入前遗传学检测的周期中,每次活检的胚胎整倍体率两组均为66.7%(50%-100%),RR 1.04(95%CI 0.92-1.17)。
  • 使用胚胎非整倍体植入前遗传学检测的患者中,每个整倍体胚胎移植的持续妊娠率在高AMH组为52%,参照组为54.1%,RR 0.95(95%CI 0.74-1.23)。

临床怎么用

  • 作者基于研究结论认为,高AMH水平(≥5 ng/mL)的供卵者可预期产生至少与AMH<5 ng/mL供卵者同样好的结局,受体和医生可对此放心。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the relationship between high antimüllerian hormone (AMH) levels in oocyte donors and embryo development and pregnancy outcomes among donor oocyte recipients. DESIGN: Retrospective cohort study. SETTING: Donor Egg Bank Database. PATIENTS: Patients undergoing in vitro fertilization using vitrified donor oocytes from 35 in vitro fertilization centers in the United States between 2013 and 2021. For each recipient, the first oocyte lot that was received with a planned insemination and embryo transfer (ET) was included. INTERVENTION: Oocyte donor-recipient cycles. MAIN OUTCOME MEASURES: Ongoing pregnancy rate (OPR) per ET. RESULTS: A total of 3,871 donor oocyte-recipient thaw cycles were analyzed. On the basis of donor AMH serum concentration, cycles were stratified into the high AMH group (AMH ≥5 ng/mL; n = 1,821) and the referent group (AMH <5 ng/mL; n = 2,050). Generalized estimating equation models were used to account for donors that contributed more than one lot of oocytes. The number of usable embryos per lot (median [interquartile range]) was significantly increased in the high AMH group (2 [2-4]) compared with the referent group (2 [1-3]) (relative risk [RR] 1.06; confidence interval [CI] 1.01-1.12). Among recipients with a planned ET, there was no difference in OPR between the high AMH group (45.4%) and the referent group (43.5%) (RR 1.04; 95% CI 0.94-1.15). Among preimplantation genetic testing for aneuploidy cycles, the embryo euploidy rate per biopsy was similar at 66.7% (50%-100%) in both groups (RR 1.04; CI 0.92-1.17). The OPR per euploid ET among patients who used preimplantation genetic testing for aneuploidy was also comparable, at 52% in the high AMH group and 54.1% in the referent group (RR 0.95; CI 0.74-1.23). CONCLUSION: This large national database study observed that there was no association between a high level of AMH (≥5 ng/mL) in oocyte donors and an OPR in the recipient after the first ET. On the basis of these findings, recipients and physicians can be reassured that oocyte donors with a high AMH level can be expected to produce outcomes that are at least as good as donors with an AMH level (<5 ng/mL).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Sarkar P, Zalles L, Caswell W, et al. Optimal antimüllerian hormone levels in oocyte donors: a national database analysis. Fertil Steril. 2023. PMID: 37949348. doi:10.1016/j.fertnstert.2023.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。